Edition:
United States

Smith & Nephew PLC (SN.L)

SN.L on London Stock Exchange

1,485.50GBp
14 Dec 2018
Change (% chg)

-14.50 (-0.97%)
Prev Close
1,500.00
Open
1,484.50
Day's High
1,493.00
Day's Low
1,474.00
Volume
2,937,014
Avg. Vol
2,207,702
52-wk High
1,548.50
52-wk Low
1,173.00

Select another date:

Wed, Dec 5 2018

U.S. FDA removes safety warning from Smith & Nephew's diabetic gel

British medical products maker Smith & Nephew said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved the removal of a safety warning on its treatment for lower extremity diabetic neuropathic ulcers.

U.S. FDA removes safety warning from Smith & Nephew's diabetic gel

Dec 5 British medical products maker Smith & Nephew said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved the removal of a safety warning on its treatment for lower extremity diabetic neuropathic ulcers.

UPDATE 1-Demand for new hips to boost Smith & Nephew profit margin

LONDON, Nov 1 Britain's Smith & Nephew expects its trading profit margin to be higher this year than last on a better performance for its hips franchise, boosting its shares.

Smith & Nephew on track to meet guidance after Q3 revenue grows

LONDON, Nov 1 British medical products maker Smith & Nephew said it was on track to meet full-year guidance after growing quarterly revenues by 3 percent, on strong demand for its artificial hips and knees in the United States and emerging markets.

Smith & Nephew sticks to full-year view as established markets recover

LONDON, July 26 Smith & Nephew, Europe's biggest artificial hip and knee maker, reiterated its full-year guidance on Thursday after its established markets returned to growth after a difficult start to the year.

Select another date: